- Physics-based software platform developer Schrödinger (NASDAQ:SDGR) announces a "significant" expansion of its work to discover novel antivirals for COVID-19 under its partnership with a philanthropic global initiative. The accelerated pace, evaluating "billions" of molecules each week, is supported by Google Cloud.
- It is leading the computational design work in an alliance with major biopharma firms, including Takeda (NYSE:TAK), Novartis (NYSE:NVS), Gilead Sciences (NASDAQ:GILD) and WuXi AppTec (OTCPK:WUXIF).
- Thus far, it has evaluated four protein targets and has used Google Cloud to support ultra-large virtual screens for two.
- Alliance partners will be responsible for acquiring and testing the most promising candidates and advancing them to lead optimization with Schrödinger's assistance.
- On another note, the company will partner with Thermo Fisher Scientific (NYSE:TMO) on extending the use of the latter's cryo-EM technology to a wider range of targets that may not be amenable to structure prediction via x-ray crystallography. Financial terms are not disclosed.
- SDGR up 3% premarket on light volume.